PATIENT ALERT: Information regarding COVID-19. 

Breast Cancer Trials

Breast Cancer Trials

  • USO 20164

    A Phase II, Multicenter, Open Label Study Of Bintrafusp Alfa (M7824) Monotherapy In Participants With HMGA2-Expressing Triple Negative Breast Cancer (MS200647_0020)

    Available at 4 locations

    View Details

  • USO 19226

    A Phase Iii Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Gdc-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer (Bo41843)

    Available at 3 locations

    View Details

  • USO 19122

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Alpelisib (BYL719) In Combination With Nab-Paclitaxel In Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha (PIK3CA) Mutation Or Phosphatase And Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation (CBYL719H12301)

    Available at 2 locations

    View Details

  • MERCK KEYLYNK MK7339-009

    An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit with First-line Chemotherapy Plus Pembrolizumab in Participants with Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)(KEYLYNK-009)

    Available at 3 locations

    View Details

  • USO 17188

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

    Available at 3 locations

    View Details